The DEA has released their emerging threat report for mid-year 2017. It is located here via the National Drug Early Warning System (NDEWS).
No new synthetic cannabinoids have been identified US drug seizures in 2017. FUB-AMB remains the most commonly identified synthetic cannabinoid with 5F-MDMB-PINACA and ADB-FUBINACA running second and third.
Fentanyl remained the most prevalent opioid detected with furanylfentanyl and U47700 running second and third. Fentanyl analogs methoxyacetylfentanyl and tetrahydrofuranfentanyl were identified for the first time in drug evidence in the US during this time period. Interestingly, with as much coverage as carfentanil has gotten from media reports, it was only fifth in the overall number of detections. Maybe that's a good thing?
The top two cathinones detected were N-ethylpentylone and dibutylone. N-ethylpentylone made up approximately 50% of all cathinone drug detections. Alpha-PVP has fallen to fourth in the list, but it is still out there.
Only two pieces of evidence were identified as NBOMe hallucinogens (25C-NBOMe and 25I-NBOME).
Tryptamines remain inconsequential in drug seizure evidence.
Other DEA emerging trend reports for 2016 and 2017 can be found here.
Drug Enforcement Administration. Emerging Threat Report. Midyear 2017.